Key result
A single intravenous dose of the aminopeptidase A inhibitor prodrug RB150 (15 mg/kg) markedly reduced mean arterial blood pressure by 29.4 mmHg in conscious DOCA-salt hypertensive rats.
Why the study?
Does the systemically active aminopeptidase A inhibitor prodrug RB150 reduce blood pressure in a salt-dependent hypertension animal model?
Population
Male Swiss mice and male WKY and DOCA-salt rats. DOCA-salt rats were used as a model of salt-dependent…
Comparison
RB150 administered intravenously or… vs Saline injection, sham-operated rats, and…
Design
Preclinical
Follow-up
Up to 48 hours for blood pressure monitoring
Authors
Loading...
Supports brain aminopeptidase A inhibition in experimental salt-dependent hypertension; leaves open translation to human therapy.
Does the systemically active aminopeptidase A inhibitor prodrug RB150 reduce blood pressure in a salt-dependent hypertension animal model?
Mean Difference: -29.4
p-value: p=<0.01
Systemic administration of the aminopeptidase A inhibitor prodrug RB150 crosses the blood-brain barrier to inhibit brain AngIII formation, significantly reducing blood pressure in a salt-dependent hypertension model.
Fournié-Zaluski et al. (2004) studied Salt-dependent hypertension. RB150 vs. Saline / Sham was evaluated on Change in mean arterial blood pressure (MABP) (-29.4 mmHg, p=<0.01). A single intravenous dose of the aminopeptidase A inhibitor prodrug RB150 (15 mg/kg) markedly reduced mean arterial blood pressure by 29.4 mmHg in conscious DOCA-salt hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: